The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VABYSMO (Roche Products Pty Ltd)
Product name
VABYSMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
faricimab
Registration type
NCE/NBE
Indication
VABYSMO is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (nAMD),
- - Diabetic macular oedema (DMO).